DEA Prescription Audits and Investigations: Triggering Events; Process Navigation; Mitigating Noncompliance Risks
Recording of a 90-minute CLE video webinar with Q&A
This CLE webinar will examine how to navigate Drug Enforcement Agency (DEA) prescription drug audits and investigations. The panel will discuss actions that could trigger audits or investigations, describe what may be expected when going through the audit or investigation process, and offer best practices for developing processes and procedures to mitigate risk of Controlled Substances Act (CSA) violations and subsequent penalties.
Outline
- Introduction
- Statutory authority
- Increased scrutiny
- DEA audits
- Purpose
- Triggers
- What to expect of the process?
- DEA investigations
- Purpose
- Triggers
- What to expect of the process?
- Preparing for potential audits and investigations; minimizing risk of violations
- Maintaining records
- Policies and procedures
- Other
- Penalties: administrative, civil, and criminal
- Practitioner takeaways
Benefits
The panel will review these and other key issues:
- What actions may trigger a DEA audit? Investigation?
- What practices should healthcare providers handling prescription drugs put into place to prepare for a potential audit or investigation and mitigate risk of noncompliance?
- What can healthcare clients expect in a DEA audit? Investigation?
- What potential penalties could clients face for CSA noncompliance?
Faculty

Natalia Mazina
Founder
Mazina Law
Ms. Mazina offers extensive experience to healthcare providers in the areas of government investigations, including... | Read More
Ms. Mazina offers extensive experience to healthcare providers in the areas of government investigations, including DEA, FDA, HHS, boards of pharmacy and medical boards; third-party audits and licensing involving PBMs, Medicaid, and Medicare; compliance with board of pharmacy, medical board, FDA and DEA regulations, PBM contracts and manuals, HIPAA and state privacy laws, and Anti-Kickback Statutes and false claims; as well as license defense. She is a frequent author and lecturer on minimizing risk in relation to controlled substances, among other matters.
Close
Dennis A. Wichern
Managing Partner
Prescription Drug Consulting
Mr. Wichern is a 30-year veteran of the DEA who formerly managed the Chicago Field Division. He currently assists... | Read More
Mr. Wichern is a 30-year veteran of the DEA who formerly managed the Chicago Field Division. He currently assists healthcare providers in navigating through the myriad of federal laws and regulations concerning prescription drugs. Mr. Wichern is a recognized expert on the dangers of the prescription drug epidemic and routinely speaks to healthcare providers to identify methods to better safeguard their practices and reduce the professional and operational risks emanating from these threats. He was the first to develop CME and CLE programs addressing MAT and pain prescribing safeguards, federal regulatory and DEA compliance, and drug destruction.
Close